Worse CF Lung Outcomes Linked with Mutations Causing Iron Overload Disorder, Study Finds
Patients with cystic fibrosis (CF) who carry certain mutations in the HFE gene, which are also behind an iron overload disorder, have...
Cystic Fibrosis Lung Function Improved With Triple Therapy
Patients with cystic fibrosis with either 1 or 2 Phe508del alleles who were treated with a drug combination of VX-659, tezacaftor, and...
Mucus, cough and chronic lung disease: New discoveries
As a cold ends, a severe mucus cough starts. Sound familiar? Two studies now give explanations: First, crucial mechanisms of the mucus in...
AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study
On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019 NEW YORK, Nov. 01, 2018...
Santhera Starting Phase 1b/2a Trial Testing Potential CF therapy POL6014
A Phase 1b/2a, dose-escalating clinical trial evaluating the effects of POL6014 in patients with cystic fibrosis (CF) was recently...
#WeCare and #MECFA advance CF care in the Middle East
“to improve and extend the lives of Cystic Fibrosis patients through disease awareness, advocacy and advanced care." MECFA The Middle...
#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators
Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco(ivacaftor) and tezacaftor (VX-661) can improve the lung function of...
PTI-808 and PTI-801 Combo Improves Lung Function in CF Patients, Phase 1 Data Show
Treatment with a combo of Proteostasis Therapeutics’ investigational CFTR modulator therapies — PTI-808, a potentiator, plus PTI-801, a...
#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Pha
Once-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by Celtaxsys, reduces the frequency...
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Pres
Pre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants Phase 2a results demonstrate RPL554 has favorable...
